A phase II/III trial of GC-1102
Phase of Trial: Phase II/III
Latest Information Update: 19 Jan 2018
At a glance
- Drugs GC 1102 (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors GC Pharma
- 19 Jan 2018 New trial record
- 17 Jan 2018 According to a Green Cross Pharma media release, the company expects to initiate patient enrollment in early 2018 and expects to complete the trial in 5 years.
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.